GE Healthcare was in the news recently with its acquisition of Thermo Fischer Scientific’s cell culture media and sera, and gene modulation and magnetic business. As the press release states this adds to GE’s “leadership in medical diagnostic technology includes its $4 billion Life Sciences business, which delivers innovative products and services for the fast-growing diagnostics, research and biopharmaceutical manufacturing sectors.” View the Press Release here.
GE’s specific capabilities in biomanufacturing will be on display at INTERPHEX, March 18-20.
“GE Healthcare Life Sciences provides tools and technologies, solutions and expertise which enable the biopharmaceutical industry to develop and manufacture biotherapeutic medicines and vaccines cost-effectively. Our products and platform solutions are designed to meet the key challenges posed at every stage in the biomanufacturing process, delivering the desired product at the required purity and safety – all with fast development and integrated solutions in mind. Across the bioprocessing spectrum, our focus is on supporting you from idea to result.”
Image via GE Healthcare